Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalfampridine in HTLV-1 associated myelopathy/tropical spastic paraparesis
IRCT20180618040127N4Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dalfampridine in HTLV-1-associated myelopathy (HAM), sponsored by Mashhad University of Medical Sciences. Started Jun 2023; status: completed.
02
Drugs
dalfampridine
03
Conditions
HTLV-1-associated myelopathy (HAM)
Beyond the preview
Go deeper on IRCT20180618040127N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180618040127N4.